Mylan (MYL) Receives FDA Approval for Generic Version of Takeda's Actoplus Met
- Top 10 News for 8/25 - 8/29: S&P 500's New Record; U.S. Q2 GDP Outpaces Views; Major Mergers Aplenty
- Pressure on U.S. to Update Terror Alert System After U.K. Raises Terror Threat Level
- American Airlines Group (AAL)/Orbitz Worldwide (OWW) Reach Agreement; American Airlines Back on Orbitz Sites
- FTC Requests Additional Info from Reynolds American (RAI), Lorillard (LO) on Pending Deal
- Digital Ally (DGLY) Warns Lofty CEO Expectations May Not Be Attainable
Bloomberg reporting Mylan (NYSE: MYL) has won FDA approval for its generic version of Takeda's actoplus met.
You May Also Be Interested In
- Mylan (MYL) Files ANDA for Generic Copaxone 40-mg/mL Injection
- UPDATE: Criteo (CRTO) Sees Sharp Move Lower; Talks with Publicis 'Unfounded' - Reuters
- Mylan's ANDA for Three Times Per Week Generic Copaxone® 40 mg/mL Accepted for Filing by FDA
Create E-mail Alert Related CategoriesFDA, Rumors
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!